AvertD Post-Approval Study

Prescient Medicine Holdings, Inc.

Summary

A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: Yes

Detailed criteria

Inclusion Criteria: * ≥18 years of age * Prior to first opioid prescription * Being considered for first oral opioid prescription (4-30 days) * Prescribed AvertD as part of care * Willing and able to complete yearly assessments for 5 years * Signed informed consent Exclusion Criteria: * Planned opioid prescription \<4 or \>30 days * Any condition making participation unsafe or infeasible per investigator judgment

Interventions

Genetic
Opioid Used Disorder Risk Assessment
Determine the likelihood of Opioid Used Disorder prior to prescribing opioids

Location

Concentrics Research
Indianapolis, Indiana